Floatz logo

Umbellatine

Metabolic Dysfunction-Associated Steatotic Liver Disease

China National Center for Cardiovascular DiseasesSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

130 Active assets in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB

View all 50 →

Same molecule, other indications

Umbellatine is also rated in:

inherited lipid metabolism disorderActive
BBB
Indicative · Phase 4
72 / 100
View asset →
abdominal obesity-metabolic syndromeActive
BB
Indicative · Phase 4
69 / 100
View asset →
prediabetes syndromeActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →